PHA SCR papain-like proteinase
(Die Seite wurde neu angelegt: „{{up|PHA pharmacophore by screened target}} {{plb|((covid19+OR+covid-19+OR+sars-cov2+OR+sars-cov-2+OR+2019-ncov+OR+2019ncov))+AND+(papain-like+OR+plpro+OR+"pl(…“) |
K |
||
| Zeile 1: | Zeile 1: | ||
{{up|PHA pharmacophore by screened target}} | {{up|PHA pharmacophore by screened target}} | ||
| − | {{plb|((covid19+OR+covid-19+OR+sars-cov2+OR+sars-cov-2+OR+2019-ncov+OR+2019ncov))+AND+(papain-like+OR+plpro+OR+ | + | {{plb|((covid19+OR+covid-19+OR+sars-cov2+OR+sars-cov-2+OR+2019-ncov+OR+2019ncov))+AND+(papain-like+OR+plpro+OR+#22pl(pro)#22)}} |
{{tp|p=32216114|t=ä. Structural and biochemical characterization of SARS-CoV papain-like protease 2 |pdf=|usr=}} | {{tp|p=32216114|t=ä. Structural and biochemical characterization of SARS-CoV papain-like protease 2 |pdf=|usr=}} | ||
Version vom 21. April 2021, 18:53 Uhr
| PHA pharmacophore by screened target |
| living current stringent pubmed readout on {{{2}}} |
32216114 ä. Structural and biochemical characterization of SARS-CoV papain-like protease 2
23788528 2013. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.
| 31765674 2020. Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease. |
| 32845033 2020. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. |
| 32850963 2020. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease. |
32874702 2020. Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches.
32962355 2020. Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors.
32979815 2020. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
| 32998368 2020. Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations. |
32999768 2020. Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs.
33043784 2020. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
33052144 2020. Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study.
33062954 2020. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
33067239 2020. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
33089730 2020. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
33201386 2020. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
33246378 2020. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
33251185 2020. Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico Methods and Benchmarking.
33276953 2020. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.
33289456 2020. Virtual screening of phytoconstituents from miracle herb nigella sativa targeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment.
33304884 2020. Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease.
33319212 2021. Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19.
32915473 2020. Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics.
33024071 2020. SARS-CoV-2: the many pros of targeting PLpro.
33106741 2020. Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation.
33176643 2020. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach Against COVID-19.
33251371 2020. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.
32691680 2020. Cyanobacterial metabolites as promising drug leads against the M(pro) and PL(pro) of SARS-CoV-2: an in silico analysis.
